This document contains information about tuberculosis (TB) infection and the problem of TB in India. It discusses that the chances of getting infected depends on duration, frequency and individual immune status of exposure. It also describes primary and post-primary TB infections. India has the highest TB burden in the world, accounting for over 1.9 million new cases annually. TB is one of the leading infectious causes of death in India, killing approximately 1000 people daily. Charts are also included showing quarterly TB case statistics for the block from 2014.
At the end of the session, the students shall be able to
Describe the HIV AIDS introduction, epidemiology of HIV AIDS, diagnosis of HIV AIDS, treatment of HIV AIDS and prevention control of HIV AIDS.
At the end of the session, the students shall be able to
Describe the HIV AIDS introduction, epidemiology of HIV AIDS, diagnosis of HIV AIDS, treatment of HIV AIDS and prevention control of HIV AIDS.
Emerging and reemerging infectious diseasesarijitkundu88
Various emerging and reemerging diseases. Factors contributing to the emergence of infectious diseases. Antibiotic resistance. The global response to control them. Laboratories network in surveillance.
Emerging and reemerging infectious diseasesarijitkundu88
Various emerging and reemerging diseases. Factors contributing to the emergence of infectious diseases. Antibiotic resistance. The global response to control them. Laboratories network in surveillance.
Epidemiology & Control measures for Tuberculosis. AB Rajar
n this Lecture I tried my best to include all essential features about the TB disease. I hope that this will help to undergraduate Medical students for better understanding the Disease.
HIV (Human Immunodeficiency Virus) infects cells of the immune system and destroys or impairs their function.
Infection progressive deterioration of the immune system breaking down the body's ability to fight out infections & diseases by opportunistic bacteria, viruses and fungi.
AIDS (Acquired Immune Deficiency Syndrome) refers to the most advanced stages of HIV infection and a collection of signs and symptoms caused by more than 20 opportunistic infections or related cancers.
Preventing TB infection in HIV-infected
individuals living in medium and high TB endemic
settings
February 5, 2016
Jeffrey D. Jenks, MD, MPH
UCSD HIV & Global Health Rounds
Presentation on HIV/AIDS, public health concern- include cause, symptoms, prevention and appropriate interventions. Also it include the Epidemiological Triangle link between agent, host and environment, Status of the disease in Nepal and in world.
Similar to Tuberculosis sensitation for lsgd by Dr.Mammen P Cherian (20)
We understand the unique challenges pickleball players face and are committed to helping you stay healthy and active. In this presentation, we’ll explore the three most common pickleball injuries and provide strategies for prevention and treatment.
QA Paediatric dentistry department, Hospital Melaka 2020Azreen Aj
QA study - To improve the 6th monthly recall rate post-comprehensive dental treatment under general anaesthesia in paediatric dentistry department, Hospital Melaka
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Immunity to Veterinary parasitic infections power point presentation
Tuberculosis sensitation for lsgd by Dr.Mammen P Cherian
1. DR.MAMMEN P CHERIAN
MBBS, PGDOR
MEDICAL OFFICER IN
CHARGE, PHC NIRANAM
MOTC THIRUVALLA TU
RNTCP
Training for LSGD
MEMBERS
CHATHENKERY
24/04/2015
2. TB Infection
• Chances of getting infected
depends on:
1. The duration of exposure
2. The frequency of exposure
3. The immune status of an
individual
3. Infection
• Entry and establishment of organism in human body
• Takes about 6-8 weeks.
• Indicated by +ve tuberculin skin test.
1. Primary infection – infection occurring for the first time in a susceptible
• Individual exposed to M.tb.
• Primary complex
• Secondary bacillary multiplication that occurs at regional LN
• 2.Post primary TB – after a latent period of many months or even years after
primary infection.
• Risk of spread of infection:
• To 10-15 persons/year for 2-3 years
• Risk factors for developing disease:
• Strongest risk factor- HIV Co-infection, DM, SMOKING, ALCOHOL ABUSE
4. India is the highest TB burden country accounting for more than one-
fifth of the global incidence
Indonesia
6%
Nigeria
5%
Other countries
20%
Other 13 HBCs
16% China
14%
South Africa
5%
Bangladesh
4%
Ethiopia
3%
Pakistan
3%
Phillipines
3%
India
21%
Source: WHO Geneva; WHO Report 2009: Global Tuberculosis Control; Surveillance, Planning and Financing
Global annual incidence = 9.4 million
India annual incidence = 1.98 million
India is 17th among 22
High Burden
Countries (in terms of
TB incidence rate)
5. WHO estimates for TB in India (2013)
Incidence of TB
disease
2.2 million per
annum
(176 per 100,000
pop. per year)
Prevalence of TB
disease
2.8 million (230 per 100,000
pop. per year)
Mortality due to
TB
270,000 per
annum
(>900/day)
(22 per 100,000
pop. per year)
6. Problem of TB in India
• Incidence: >1.98 million new TB cases annually
– 0.8 million new infectious cases
– 75 NSP cases / 100,000 population / year
– Incidence more in north and less in south
– Incidence more in urban areas
– TB is more common among males
• Prevalence:
– WHO estimate (2007) – 3.3 million TB cases
• Deaths: about 2,76,000 deaths due to TB each year
– One of the leading infectious cause of death
– Nearly 1000 deaths due to TB per day; about 2 deaths every 3 minutes
7. Problem of TB in India..
• Infection: 40% (~400m) infected with tuberculosis bacteria
– Only 10% of them will develop TB disease in lifetime
– Co-infection with HIV increases risk of TB disease by 6 to 8 times
– Several other factors also increase this risk, e.g. diabetes, smoking, poor
nutrition, etc
• HIV :
1. 2.27 million people living with HIV; nearly 1 million co-infected with HIV and TB
2. About 5% of TB patients estimated to be HIV positive
3. HIV in TB varies greatly between districts and states (<1% to 14%)
4. More in south (except Kerala), north-east and some scattered districts
• Estimated Multi-drug resistant TB
1-3% in new cases
12-17% in re-treatment cases
• DM, SMOKING
8. Estimated* Incidence of TB in India
(No. of NSP Cases per 100,000 population, per year)
National 75
North Zone 95
East Zone 65**
West Zone 80
South Zone 50**
North
West East
South
* Estimated from ARTI survey
** For programme monitoring
purpose estimated cases in East &
South zones have been kept at the
national level of 75
ARTI survey by NTI 2001-2003
9. Annual Risk of Tuberculosis Infection(ARTI)
Proportion of population that gets newly
infected ( or re-infected ) with tubercle
bacilli during the course of one year
ARTI for the country is 1.5%.
For Kerala it is 1.0%
203 cases per lakh population is
infected each year.
135 cases/L/Year-Kerala
Type of case Occurrence /
lakh / year
NSP (Definitive) 75 cases
NSN (Probable) 75 cases
Previously
treated
38 cases
EP 15 cases
Total 203 cases
Type of case Occurrence /
lakh / year
NSP (Definitive) 50 cases
NSN (Probable) 50 cases
Previously
treated
25 cases
EP 10 cases
Total 135 cases